Genentech/Roche blazing new trails with Perjeta, GA101
This article was originally published in Scrip
Executive Summary
While GA101 (obinutuzumab) and Perjeta (pertuzumab) – both from Genentech and its parent company Swiss drug maker Roche – are two different types of medicines targeting different indications, they shared a common bond this week in winning FDA priority reviews just days apart, putting the products on an expedited road to US approval.